| ²é¿´: 325 | »Ø¸´: 1 | ||
cainiaoduiгæ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
In addition to tumor studies using anti-DLL4 as a single agent, additive anti-tumor activity was observed in combination with anti-VEGF therapy in a majority of tested tumor models. Since angiogenic sprouting after DLL4 blockade remains a VEGF-dependent process , DLL4 inhibition may increase the dependency of the tumor microvasculature on a VEGF-mediated survival signal. In anti-Dll4 treated neonatal mouse retinas, there was a defect in arteriogenesis with a complete absence of pericyte coverage of the retinal vessels . Soluble DLL4 was also able to reduce the recruitment of pericytes in a murine xenograft tumor model. |
» ²ÂÄãϲ»¶
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ085600Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
»¯Ñ§µ÷¼Á
ÒѾÓÐ17È˻ظ´
qiaoxiaojing
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 2
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 667.8
- ºì»¨: 1
- Ìû×Ó: 102
- ÔÚÏß: 42.9Сʱ
- ³æºÅ: 2125162
- ×¢²á: 2012-11-13
- ÐÔ±ð: MM
- רҵ: ÉúÎﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-15 10:25:14
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-01-19 08:37:12
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-15 10:25:14
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-01-19 08:37:12
|
³ýÁ˽«¿¹-DLL4×÷Ϊµ¥Ò©ÓÃÓÚÖ×ÁöÑо¿Í⣬ͬʱ¹Û²ìÁË¿¹Ö×Áö»îÐÔµÄÌí¼Ó¼ÁÁªºÏ¿¹-VEGFÖÎÁÆÔڴ󲿷ÖÖ×Áö²âÊÔÄ£ÐÍÖеÄ×÷Óá£DLL4ÒÖÖÆÑª¹ÜÉú³ÉºóÈÔÈ»±£³ÖÒÀÀµVEGFµÄ¹ý³Ì£¬DLL4ÒÖÖÆ¿ÉÄÜÔö¼ÓÖ×Áö΢Ѫ¹ÜÉÏVEGF½éµ¼µÄ´æ»îÐźŵÄÒÀÀµÐÔ¡£ÔÚ¿¹DLL4´¦ÀíµÄÐÂÉúСÊóÊÓÍøÄ¤ÉÏ£¬ÔÚ¶¯ÂöÖдæÔÚÊÓÍøÄ¤Ñª¹ÜÍêȫûÓÐÖÜϸ°û¸²¸ÇµÄȱÏÝ¡£¿ÉÈÜÐÔµÄDLL4»¹Äܹ»½µµÍÖÜϸ°ûÔÚСÊóÒìÖÖÒÆÖ²ÁöÄ£ÐÍÖеľۼ¯¡£ ÐÂÊÖ·Ò룬Çë¶àÖ¸½Ì~ |
2Â¥2014-01-09 08:51:30














»Ø¸´´ËÂ¥